People: Merrimack Pharmaceuticals Inc (MACK.W)
MACK.W on CBOE When Trading NASDAQ Global Select Market
5.53USD
17 May 2013
5.53USD
17 May 2013
Price Change (% chg)
$0.05 (+0.91%)
$0.05 (+0.91%)
Prev Close
$5.48
$5.48
Open
$5.53
$5.53
Day's High
$5.55
$5.55
Day's Low
$5.53
$5.53
Volume
911
911
Avg. Vol
1,066
1,066
52-wk High
$10.90
$10.90
52-wk Low
$4.21
$4.21
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Gary Crocker |
2005 | Independent Chairman of the Board | |
Robert Mulroy |
47 | 1999 | President, Chief Executive Officer, Director |
William Sullivan |
40 | 2011 | Chief Financial Officer, Treasurer |
Clet Niyikiza |
53 | 2010 | Executive Vice President - Development |
Ulrik Nielsen |
39 | 2009 | Chief Scientific Officer, Senior Vice President |
Fazal Khan |
62 | 2006 | Senior Vice President - Manufacturing |
William McClements |
48 | 2011 | Senior Vice President - Corporate Operations |
Edward Stewart |
41 | 2011 | Senior Vice President and President, Merrimack Healthcare Solutions |
John Mendelsohn |
2012 | Director | |
James Quigley |
2012 | Director | |
James van Dresser |
70 | 1999 | Independent Director |
Gordon Fehr |
78 | 1999 | Independent Director |
Sarah Nash |
59 | 2006 | Independent Director |
Michael Porter |
65 | 2010 | Independent Director |
Anthony Sinskey |
72 | 1999 | Independent Director |
Biographies
| Name | Description |
|---|---|
Gary Crocker |
Mr. Gary L. Crocker is Independent Chairman of the Board of Merrimack Pharmaceuticals Inc. He has served as a member of board of directors since 2004 and as chairman of board of directors since 2005. Mr. Crocker is President, Manager and Chairman of Crocker Ventures, LLC, a privately-held life science investment firm funding differentiated technologies in the areas of biotechnology and medical devices. Mr. Crocker has held senior executive positions or served on the board of directors of several privately-held life science companies, including as chairman of the board of ARUP Laboratories, co-founder and director of Theratech, Inc., President and Chief Executive Officer, founder and member of the board of directors of Research Medical, Inc. and as a member of the board of directors of Interleuken Genetics, Inc., The Med-Design Corporation and LineaGen Genetics, LLC. Mr. Crocker served as a member of the board of the Federal Reserve Branch of San Francisco from 1999 to 2007. Mr. Crocker also serves as a member of the board of directors of Sorenson Legacy Foundation. Mr. Crocker holds an M.B.A. and a B.S. in economics from Harvard University. |
Robert Mulroy |
Mr. Robert J. Mulroy is President, Chief Executive Officer, Director of Merrimack Pharmaceuticals Inc. Prior to joining, Mr. Mulroy worked as a management consultant in the pharmaceutical and healthcare industries. Mr. Mulroy has also worked as a consultant in the field of international development and has served as an advisor to multiple start-up companies in the biotechnology industry. Mr. Mulroy holds a master's degree in public and private management from Yale University and a B.A. from Stanford University. |
William Sullivan |
Mr. William A. Sullivan is Chief Financial Officer, Treasurer of Merrimack Pharmaceuticals Inc. He has served as Chief Financial Officer since May 2011 and Treasurer since February 2010. Mr. Sullivan served as Controller from November 2007 to February 2010 and Vice President of Finance from February 2010 to May 2011. Previously, Mr. Sullivan served as Corporate Controller of Vette Corp., a thermal management solutions company, from October 2004 to November 2007. Mr. Sullivan began his career at Arthur Andersen LLP, where he obtained his certified public accountant license. Mr. Sullivan holds an M.B.A. and an M.S. in accounting from Northeastern University's Graduate School of Professional Accounting and a B.A. in economics from Williams College. |
Clet Niyikiza |
Dr. Clet M. Niyikiza, Ph.D., is Executive Vice President - Development of Merrimack Pharmaceuticals Inc. Dr. Niyikiza served as Senior Vice President of Product Development from July 2009 to February 2010. Previously, Dr. Niyikiza served as Vice President and Medicine Development Leader at GlaxoSmithKline, overseeing product development and global anti-cancer medicine development strategy, from 2005 to July 2009. Prior to that, Dr. Niyikiza held multiple high level positions at Eli Lilly and Company, where he ultimately led the oncology translational and applied genomics research division. Dr. Niyikiza holds a Ph.D. in mathematical sciences and an M.A. in mathematics from Indiana University. |
Ulrik Nielsen |
Dr. Ulrik B. Nielsen, Ph.D., is Chief Scientific Officer, Senior Vice President of Merrimack Pharmaceuticals Inc. Dr. Nielsen has also served as President and Chief Executive Officer and as a member of the board of directors of Silver Creek Pharmaceuticals, Inc., since July 2010. Dr. Nielsen was one of co-founders and has been research and drug discovery since March 2002, first as Director of Research from March 2002 to December 2004 and then as Vice President of Research from January 2005 to February 2009. Prior to joining, Dr. Nielsen was a post-doctoral fellow at The Massachusetts Institute of Technology, or MIT, where he researched the interface among biology, engineering and computational biology. Dr. Nielsen holds a Ph.D. in molecular biology and an M.S. in biochemistry from the University of Copenhagen. |
Fazal Khan |
Dr. Fazal R. Khan, Ph.D., is Senior Vice President - Manufacturing of Merrimack Pharmaceuticals Inc. Prior to joining, Dr. Khan served as Vice President of Manufacturing for Cellective Therapeutics, Inc., Vice President of Manufacturing Operations at Human Genome Sciences and Director of Biopharmaceuticals Development and Manufacturing at Hoffmann-LaRoche, Inc. Dr. Khan holds a Ph.D. and an M.S. in biochemistry and a B.S. in biology from Aligarh University in India. |
William McClements |
Mr. William M. McClements is Senior Vice President - Corporate Operations of Merrimack Pharmaceuticals Inc. Previously, Mr. McClements served as Chief Human Resources Officer of Integreon Managed Solutions, Inc., a global research and business services company, from May 2010 to September 2011. Prior to that, Mr. McClements served as Chief Operating Officer and a partner at Monitor Group, a global strategic advisory firm, where he worked from 1987 to May 2010. From September 2009 to March 2010, Mr. McClements also served as Acting President of Be the Change Inc., a non-profit focused on creating national issue-based campaigns. Mr. McClements holds an M.B.A. from Harvard University and a B.A. from Williams College. |
Edward Stewart |
Mr. Edward J. Stewart is Senior Vice President and President, Merrimack Healthcare Solutions, a subsidary of Merrimack Pharmaceuticals Inc. Mr. Stewart served as Director of Business Development from August 2001 to July 2006, as Senior Director of Business Development from August 2006 to July 2007 and as Vice President of Business Development from July 2007 to March 2009. Mr. Stewart began his career at KPMG Peat Marwick LLP in the life sciences strategy consulting group. Mr. Stewart holds an M.B.A. from the Johnson Graduate School of Management at Cornell University and a B.S. in biology from Bates College. |
John Mendelsohn |
Dr. John Mendelsohn, M.D., has been appointed as Director of Merrimack Pharmaceuticals, Inc., with effect from June 13, 2012. Dr. Mendelsohn, an internationally cancer research, served as president of MD Anderson from 1996 to 2011 and remains on the faculty as co-director of the new Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. Mendelsohn is recognized for his research on the binding of growth factors to cell surface receptors and how they regulate cell functions. Mendelsohn earned his bachelor's degree in sciences magna cum laude from Harvard College in 1958. He was the first undergraduate student of James D. Watson, Ph.D., who later won the Nobel Prize in Medicine for identifying the structure of DNA. After spending a year in Scotland as a Fulbright Scholar in biochemistry, Mendelsohn received his medical degree cum laude from Harvard Medical School in 1963. He was founding director of the cancer center at University of California San Diego in 1977 and served as Chairman of Medicine at Memorial Sloan-Kettering Cancer Center 1985-1996, before moving to MD Anderson. |
James Quigley |
Mr. James H. Quigley has been appointed as Director of Merrimack Pharmaceuticals, Inc., effective July 16, 2012. Quigley recently retired as a Senior Partner with Deloitte LLP. He is the co-author of "As One: Individual Action, Collective Power" (2011), a book that addresses the leadership challenge of creating environments that inspire groups to work together toward a common goal. Quigley is engaged in numerous business organizations and committees and brings a history of involvement in various business and community groups including being the U.S. co-chairman of the TransAtlantic Business Dialogue, a member of the Council on Competitiveness and a former member of the U.S. Securities and Exchange Commission (SEC) Advisory Committee on Improvements to Financial Reporting. Quigley earned a Bachelor of Science degree and an honorary Doctorate of Business from Utah State University. He was awarded an honorary degree of Doctor of Commercial Science from Bentley College in Waltham, Massachusetts. |
James van Dresser |
Mr. James van B. Dresser is Independent Director of Merrimack Pharmaceuticals Inc. From 1970 until his retirement in 1997, Mr. Dresser held various consulting and leadership positions at The Boston Consulting Group, including serving as the firm's first Chief Administrative Officer from 1982 to 1997. Mr. Dresser served on the Board of Trustees of Wesleyan University from 1990 until 1993 and again from 1995 until 2009, when he also served as the chairman of the Board of Trustees. Mr. Dresser currently serves as a selectman for the Town of Salisbury, Connecticut. Mr. Dresser holds an M.B.A. from Harvard University, an M.A. from the Fletcher School of Law and Diplomacy at Tufts University and a B.A. from Wesleyan University. |
Gordon Fehr |
Mr. Gordon J. Fehr is Independent Director of Merrimack Pharmaceuticals Inc. Mr. Fehr also currently serves on the board of directors of the Research Institute of McGill University Health Centers. In 1963, Mr. Fehr joined Pfizer Canada, Inc., or Pfizer Canada, as the Assistant to the President of Pfizer Canada and later became Pfizer Canada's Controller and the General Manager of the Chemical Division. In 1972, Mr. Fehr was named Chairman and President of Pfizer Canada, a position he held until his retirement in 1994. Mr. Fehr served as a member of the board of directors of Labopharm, Inc. from 1998 to 2007. Mr. Fehr also served as President and Chairman of the Montreal Board of Trade from 1983 to 1984 and as a member of board of directors of the Montreal Airport Authority from 1992 to 2002. In addition, Mr. Fehr has served on advisory boards for the National Research Council's Biotechnology Research Institute and the Montreal Center of Innovative Technology, where he was Chairman of the biotechnology committee. Mr. Fehr holds a B.Eng. in chemical engineering from McGill University. |
Sarah Nash |
Ms. Sarah E. Nash is Independent Director of Merrimack Pharmaceuticals Inc. Ms. Nash also currently serves on the boards of directors of Knoll Inc. and Blackbaud Inc. From 2000 until her retirement in 2005, Ms. Nash served as vice chairman of JPMorgan Chase & Co.'s Investment Bank where she was responsible for the firm's client relationships. Prior to that, Ms. Nash was the Regional Executive and Co-Head of Investment Banking for North America at JPMorgan Chase & Co. Previously, Ms. Nash served on the board of directors of Pathmark Stores, Inc. from 2005 to 2009 and AbitibiBowater from 2010 to 2011. Ms. Nash also serves as a Trustee for the New York-Presbyterian Hospital, a Trustee of Washington and Lee University and on the boards of The New York Historical Society, The New York Restoration Project and the Business Leadership Council of The City University of New York. Ms. Nash holds a B.A. from Vassar College. |
Michael Porter |
Professor Dr. Michael E. Porter, Ph.D., is Independent Director of Merrimack Pharmaceuticals Inc. Dr. Porter is the Bishop William Lawrence University Professor at Harvard Business School and has been on the faculty at Harvard Business School since 1973. Dr. Porter also serves on the boards of directors of Parametric Technology Corporation and Thermo Fisher Scientific Inc. Dr. Porter has written on healthcare delivery and has worked with healthcare providers in multiple countries and with government on healthcare policy issues. Dr. Porter holds a Ph.D. in business economics from Harvard University, an M.B.A. from Harvard Business School and a B.S.E. in aerospace and mechanical engineering from Princeton University. |
Anthony Sinskey |
Dr. Anthony J. Sinskey, Sc.D., is Independent Director of Merrimack Pharmaceuticals Inc. Dr. Sinskey is a Professor of Microbiology and Engineering Systems at MIT and a Professor of Health Sciences and Technology at the Harvard-MIT Division of Health Sciences and Technology, and he has been a member of the faculty at MIT since 1968. Dr. Sinskey also holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership Program and as Faculty Director of the Center for Biomedical Innovation. Dr. Sinskey is a co-founder and a member of the boards of directors of Metabolix, Inc. and Tepha, Inc. and a consultant to several chemical and biotechnology companies. Dr. Sinskey received an Sc.D. from MIT and a B.S. from the University of Illinois, and he was a post-doctoral fellow at the Harvard School of Public Health. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Gary Crocker |
-- |
Robert Mulroy |
645,799 |
William Sullivan |
435,682 |
Clet Niyikiza |
702,409 |
Ulrik Nielsen |
670,621 |
Fazal Khan |
690,770 |
William McClements |
-- |
Edward Stewart |
-- |
John Mendelsohn |
-- |
James Quigley |
-- |
James van Dresser |
-- |
Gordon Fehr |
-- |
Sarah Nash |
-- |
Michael Porter |
-- |
Anthony Sinskey |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Gary Crocker |
0 | 0 |
Robert Mulroy |
82,481 | 209,311 |
William Sullivan |
0 | 0 |
Clet Niyikiza |
0 | 0 |
Ulrik Nielsen |
0 | 0 |
Fazal Khan |
0 | 0 |
William McClements |
0 | 0 |
Edward Stewart |
0 | 0 |
John Mendelsohn |
0 | 0 |
James Quigley |
0 | 0 |
James van Dresser |
0 | 0 |
Gordon Fehr |
0 | 0 |
Sarah Nash |
0 | 0 |
Michael Porter |
0 | 0 |
Anthony Sinskey |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
MULROY ROBERT J |
50,000 | $2.19 |
STEWART EDWARD J |
5,000 | $2.19 |
DRESSER JAMES VAN B |
15,000 | $2.19 |
NIELSEN ULRIK B |
10,483 | $2.19 |
NIELSEN ULRIK B |
10,483 | $5.40 |
SINSKEY ANTHONY J |
15,000 | $2.19 |
FEHR GORDON J |
15,000 | $6.04 |
FEHR GORDON J |
15,000 | $2.19 |
NIYIKIZA CLET M |
41,507 | $2.12 |
MULROY ROBERT J |
58,290 | $0.00 |
MULROY ROBERT J |
7,443 | $0.00 |
CROCKER GARY L |
39,000 | $0.00 |
CROCKER GARY L |
15,015 | $0.00 |
CROCKER GARY L |
15,015 | $0.00 |
CROCKER GARY L |
39,000 | $0.00 |
CROCKER GARY L |
90,090 | $0.00 |
NIYIKIZA CLET M |
100,000 | $2.12 |
KHAN FAZAL R |
25,000 | $1.71 |
PORTER MICHAEL E |
15,000 | $2.19 |
KHAN FAZAL R |
25,000 | $6.41 |
MENDELSOHN JOHN |
5,000 | $6.63 |
CROCKER GARY L |
36,500 | $6.77 |
KHAN FAZAL R |
25,000 | $1.71 |
KHAN FAZAL R |
25,000 | $6.73 |
PORTER MICHAEL E |
10,000 | $6.08 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
